Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
TCRX
#3152
TScan Therapeutics, Inc. Common Stock
1.0
6
-3.64%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
-3.64%
Aylık değişim
-4.50%
6 aylık değişim
-43.32%
Yıllık değişim
-48.29%
Önceki kapanış
1.1
0
Open
1.0
6
Bid
Ask
Low
1.0
6
High
1.0
6
Hacim
6
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
TCRX
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2021
2022
2023
2024
TTM
Cash from operating activities
48.68 M
66.5 M
61.36 M
110.82 M
130.73 M
Cash from investing activities
9.94 M
4.22 M
60.76 M
52.61 M
67.25 M
Cash from financing activities
189.67 M
29.36 M
135.44 M
208.76 M
46.1 M
Free cash flow
38.74 M
62.28 M
58.21 M
107 M
125.61 M
Haberler
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Tscan Therapeutics conserve sa note Neutre chez BTIG après l’événement ASH
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event
TScan to host KOL event discussing updated ALLOHA trial data
Morgan Stanley dégrade l’action Tscan Therapeutics suite aux essais retardés
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials
Le BPA de Tscan Therapeutics a dépassé les attentes de 0,06$, le CA a surpassé les prévisions